Study of cervicovaginal fetal fibronectin status to guide treatment of threatened preterm labour

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 38, Issue 2, 1998, Pages 185-187

  Watson, David L ^a   Kim, Stephano J ^b   Humphrey, Michael D ^b,c  

^a TOWNSVILLE HOSPITAL   (Australia)

^b CAIRNS BASE HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CORTICOSTEROID; FETOPROTEIN; FIBRONECTIN; VITAMIN K GROUP;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; FEMALE; HUMAN; MEDICAL ASSESSMENT; PATIENT CARE; PREMATURE LABOR; PRIORITY JOURNAL; PROGNOSIS; TOCOLYSIS; UTERINE CERVIX; UTERINE CERVIX DILATATION; VAGINA;

EID: 0031807363     PISSN: 00048666     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1479-828X.1998.tb02998.x     Document Type: Article

References (15)

1. McCormack ML. The contribution of low birthweight to infant mortality and childhood morbidity N Engl J Med 1985; 312: 82-90.
2. Creasy RK. Preterm Birth Prevention: Where are we? Am J Obstet Gynecol 1993; 168: 1223-1230.
3. Tucker JM, Goldenberg RL, David RO et al. Etiologies of Preterm Birth in an Indigent Population: Is prevention a logical expectation. Obstet Gynecol. 1991; 77: 343-347.
4. Hewit BG, Newnham JL. A review of the obstetric and medical complications leading to the delivery of infants of very low birth-weight, Med J Aust 1988; 144: 234-242.
5. King JK, Grant A, Keirse MJ et al. Beta-Mimetics in preterm labour; An overview of the randomized controlled trials. Br J Obstet Gynecol 1988; 95: 211-222.
6. Kitchen W, Ford G, Orgill A, Richards A Outcome of extremely low birth-weight infants in relation to the hospital of birth. Aust NZ J Obstet Gynaecol 1984; 24: 1-5.
7. Ingemarsson MD, Arulkumaran D, Kottegoda SR et al. Complications of Beta-Mimetic therapy in preterm labour, Aust NZ J Obstet Gynecol 1985; 25: 182-189.
8. Norton ME, Merrill J, Cooper BAB. Neonatal Complications after the administration of Indomethacin for preterm labour. N Engl J Med 1993; 329: 1602-1607.
9. Matsuula H, Takiok, Titam K et al. The oncofetal structure of human fibronectin determined by monoclinal antibody FDC-6. J Biol Chem 1988; 263: 3314-3322.
10. Lockwood CJ, Senyel AE, Dische MR et al. Fetal Fibronectin in Cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991; 325 669 - 674.
11. Morrison JC, Albert JR. McLaughlin BN et al. Oncofetal fibronectin in patients with false labour as a predictor of preterm delivery. Am J Obstet Gynecol 1993; 168: 538 - 542.
12. Iams JD, Casal D, McGregor JA et al. Fetal Fibronectin improves the accuracy of diagnosis of preterm labour. Am J Obstet Gynecol 1995; 173: 141 - 145.
13. Parker J, Bell R, Brennecke S et al Fetal fibronectin in the cervicovaginal fluid of women with threatened preterm labour as a predictor of delivery before 34 weeks' gestation. Aust NZ J Obstet Gynecol 1995; 35: 3: 257 - 261.
14. Malak TM, Sizmur F, Bell SC et al. Fetal fibronectin in cervicovaginal secretions as a predictor of preterm birth. Br J Obstet Gynecol 1996; 103: 648 - 653.
15. Bartnicki J, Casal D, Kreaden US, Saling E, Vetter K. Fetal fibronectin in vaginal specimens predicts preterm delivery and very-low-birth-weight infants. Am J Obstet Gynecol 1996; 174: 971-974.